This article is more than 5 years old. Information may no longer be current.
Knowledge of use of cannabinoid molecules lacking in rheumatologists
Click Here to Manage Email Alerts
When it came to the use of cannabinoid molecules for the treatment of arthritis, in general, rheumatologists lacked confidence in their knowledge of cannabinoid molecules and in their competence to prescribe any cannabinoid for rheumatic complaints, according to results of a recently published study.
Researchers used an online questionnaire circulated to the entire Canadian Rheumatology Association membership to record the confidence of rheumatologists in their knowledge of cannabinoid molecules and mechanisms relevant to rheumatology, as well as their ability to advise patients about cannabinoid treatments.
Of the 128 respondents, three quarters reported lack of confidence in their knowledge of cannabinoid molecules. Researchers found that 25% of respondents supported any use of herbal cannabis while 45% believed there was no current role for cannabinoids in rheumatology patient care. Due to 70% of respondents never having previously prescribed or recommended any cannabinoid treatment, such as medical marijuana, there was a prevalence of uncertainty about good prescribing practices and the concerns about the risks of cannabis use were in line with current literature, according to study results.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts